Reference drugs for triple combination test drug in Russia [Design Issues]

posted by mittyri – Russia, 2019-11-15 22:29 (435 d 07:32 ago) – Posting: # 20811
Views: 3,253

Hi PharmCat!

» Anyway can be some exceptions when this rule not work. May be it can be orphan drugs or some individual cases or regulatory abuse.
"The exception that proves the rule"
Just what I have found in GRLS and that drugs were approved within a BE study against 2 Reference drugs
Amlodipine + Indapamide + Perindopril
Losartan + Amlodipine + Rosuvastatin
Indapamide + Rosuvastatin + Perindopril
(could be more, lazy to search)

I would not name it 'orphan' or 'individual' :-)
Generic companies did develop almost all attractive double combinations for cardiovasulcar diseases and were trying to expand to triple combinations.

Kind regards,
Mittyri

Complete thread:

Activity
 Admin contact
21,310 posts in 4,445 threads, 1,489 registered users;
online 4 (0 registered, 4 guests [including 4 identified bots]).
Forum time: Sunday 06:02 UTC (Europe/Vienna)

Every man gets a narrower and narrower field of knowledge
in which he must be an expert in order to compete with other people.
The specialist knows more and more about less and less
and finally knows everything about nothing.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5